- Trial phase
- Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- Time to market
- Unknown, still in Phase 1a dose-escalation with no Phase 2/3 timelines set. If successful through Phase 1b, a registrational path would be several years away.
- Why 4/10
- NX-1607 is still in Phase 1a dose-escalation (enrollment complete as of Q2 2026); there is no scheduled PDUFA, registrational readout, or any hard dated binary catalyst within the next ~12 months. The company is "reviewing data to determine next steps." Per the rubric, a mid-stage drug with no imminent binary catalyst scores 3-5; combined with the fact that NX-1607 is not Nurix's lead asset (bexobrutideg is, partnered with Roche), this caps the score at 4.
NX-1607 is an early-stage, first-in-class asset that is not the primary value driver for NRIX (that's bexobrutideg, which Roche partnered for up to $2.3B). Phase 1a data showing 49.3% DCR is encouraging but too early for pivotal conclusions. Watch for when the company announces Phase 1b expansion plans or presents updated data at a medical conference, no specific date is set. For now, NX-1607 is a pipeline free option on a novel immuno-oncology mechanism, not a standalone reason to trade NRIX.
Price Chart
Executive Summary
NX-1607 is Nurix Therapeutics' first-in-class oral CBL-B inhibitor, a novel immuno-oncology agent that reactivates T cells and NK cells by releasing an intracellular immune brake. Phase 1a data (ESMO 2025) showed a 49.3% disease control rate in 82 heavily pretreated patients across 11 solid tumor types, including a confirmed partial response in a patient with MSS colorectal cancer (a notoriously immunotherapy-resistant tumor) who stayed on treatment for 27 months. As of Q2 2026, Phase 1a dose escalation enrollment is complete and the company is reviewing data to determine next steps. NX-1607 is not Nurix's lead asset, that distinction belongs to bexobrutideg (a BTK degrader partnered with Roche for up to $2.3B). The stock is driven primarily by the bexobrutideg story. NX-1607 is an early-stage pipeline component with encouraging but non-pivotal data and no imminent binary catalyst.
How It Works
NX-1607 is an oral pill that works as an "intramolecular glue", it locks a protein called CBL-B into a closed, inactive shape. CBL-B acts as a brake on the immune system's T cells and NK cells (the body's cancer-fighting infantry). By releasing this brake, NX-1607 reactivates immune cells to attack tumors. It's a novel approach to immunotherapy, rather than blocking PD-1/PD-L1 like Keytruda, it targets a different immune checkpoint inside the cell. Preclinical studies show it can reverse T-cell exhaustion and work both alone and with PD-1 inhibitors.
Trial Status
As of July 9, 2026 (Q2 2026 earnings), Nurix has completed enrollment of the current Phase 1a dose escalation cohorts of NX-1607 across multiple solid tumor types and is reviewing the data to determine next steps. The Phase 1a portion (NCT05107674) enrolled 82 patients across 11 tumor types with 6 once-daily and 5 twice-daily dosing regimens (5-80 mg total daily dose). Phase 1b expansion in select tumor types (including DLBCL) is planned but not yet initiated. Data was presented at ESMO 2025 and SITC 2025.
The Two-Sided Case
Upcoming Catalysts
- Announcement of Phase 1b expansion plans and dose selection (timing uncertain, company is 'reviewing data to determine next steps')
- Potential updated NX-1607 data presentation at a future medical conference (no specific conference announced)
- Any corporate update on next development steps for NX-1607 in future earnings calls
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Nurix Therapeutics, Inc. PRESS-RELEASE NRIX ·Originating report